Harwell Oxford, November 17, 2025, MitoRx Therapeutics Limited (MitoRx), a biotech companydeveloping novel classes of mitochondrial-targeted agents targeting obesity, todayannounces a GBP 5.5 million (USD 7.2 million) pre-Series A fundraise.

The investment will be used to progress development of MitoRx’slead mitochondrial-targeted program, Myo-004, throughclinical candidate selection. Myo-004 is a first-in-class injectable small molecule designedto achieve weight loss, without loss of lean mass. Thefunding will also support an on-going oral programwithin MitoRx’s Candidate Engine, a platform for the generation and profilingof additional candidates.

The pre-Series A financing was led by Oshen Holdings SA (Luxembourg)with significant participation from existing investors. This fundraise follows a recent series of compelling preclinical data presented at leadingconferences throughout 2025.  Data presented at the 32nd European Conferenceon Obesity, showed that Myo-004 monotherapy drives fat loss while preserving lean mass. Whencombined with semaglutide, Myo-004 further enhanced fat loss while preservinglean mass [1]. At the American Diabetes Association’s 2025 Scientific Sessions,results were presented that demonstrate that Myo-004 restoredinsulin sensitivity in an industry-standard murine diet-induced obesity model [2]. Additionaldata presented at European Association for the Study of Diabetesannual meeting highlight Myo-004’s role in musclepreservation and liver-fat clearance in obesity. The preclinical data findings also revealed increased muscle fiber size in diet-induced obesity cohorts treated withMyo-004, confirming lean mass gains observed via MRI analysis [3].

“This MitoRx fundraise clearly showsinvestors understand that protection of lean mass including muscle is key totherapeutic weight loss. Our small molecules drive fat loss whilepreserving lean mass through a unique mechanism of action, said Jon Rees, CEO and Co-founder, MitoRxTherapeutics. “This Pre-Series A fundraise will enable MitoRx tocomplete a comprehensive data package demonstrating that its novel mitochondrial-targetedagents are efficacious, safe and well tolerated solutions for people livingwith obesity, driving a better quality of weight loss than GLP-1receptor agonists.”

“Obesity has reached unprecedented levels,affecting close to 900 million people worldwide and continuing to riseexponentially,” said Justin Cahill,Managing Partner of Oshen Holdings SA. “While GLP-1 therapies have marked an important step forward, emergingdata make it clear they are not the long-term answer. People living withobesity need next-generation solutions that deliver sustainable weight controlwith fewer side-effects and broader metabolic benefits. MitoRx’s compellingpreclinical data package positions it at the forefront of this next wave ofinnovation. The company’s approach demonstrates meaningful reductions in bodyand liver fat while preserving muscle mass and insulin sensitivity - keydifferentiators from current standard treatments. We are delighted to backMitoRx in its mission to develop a truly differentiated, long-term therapeuticsolution to address the escalating global obesity crisis.”

As part of thefinancing, Didier Cowling, Managing Partner of Oshen Holdings SA, has joinedMitoRx's Board of Directors, strengthening the company’s strategic leadershipas it advances its promising therapies.